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The expression ‘hypertensive urgencies’ includes many diseases. The unifying features of these diseases are a high
level of arterial pressure and acute distress of one or more organs. The aim of the review was to define the idea of
the ‘acute hypertension’ as a new concept, different from ‘chronic hypertension’. Acute hypertension might be
related to ‘organ damage’ because it is the cause, the consequence or an effect of the acute stress. We compounded a
narrative review which has included analyses of 373 articles. The structure of the search strategy included a literature
search of PubMed, MEDLINE, Cochrane Library and Google Scholar databases. We applied the following inclusion
criteria: prospective double-blind randomised controlled trials, experimental animal work studies, case–control studies
and recruiting patients representative of the general sick population. In this review, the diseases included in the term
‘hypertensive emergencies’ share ‘acute’ hypertension. This is a new idea that emphasises the suddenly increased
arterial pressure, irrespective of the initial arterial pressure and independent of the goals of hypertension control.
The ‘hypertensive emergencies’ have been grouped together in three subsets: (1) diseases that result from acute
hypertension that is caused by faulty regulation of the peripheral circulation (acute primary hypertension), (2) diseases
that produce hypertension (acute secondary hypertension) and 3) diseases that have hypertension as an effect of the
acute stress caused by the principle disease (acute associated hypertension). This review highlights a novel idea: acute
hypertension is a common sign of different diseases characterised by the sudden surge of arterial pressure, so
overwhelming the difference between hypertensive emergencies and urgencies. The judgment of acute hypertension
is independent of the initial arterial pressure, normotension or hypertension and is linked with the transient failure of
the baroreflex. Hypertensive emergencies are grouped together because all of these diseases require prompt therapy
to prevent the negative outcomes of acute hypertension
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This work was performed with the aim to make further
distinctions between ‘hypertensive emergencies’ and ‘hyper-
tensive urgencies’. The words do not seem appropriate to
the clinical importance and are misinterpreted. An increase
in arterial pressure alone is not sufficient for grouping these
different diseases, which share one sign only. It is difficult
to unify diseases with such different clinical features.
In accordance with the literature, we define ‘hyperten-
sive emergencies’ as the sudden and prolonged increase
of arterial pressure related to ‘organ damage’ and causing
poor outcomes.* Correspondence: alfonso.lagi1@tin.it
Emergency & Accident Unit, Ospedale Santa Maria Nuova, ASL 10, Florence,
Italy
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this article, unless otherwise stated.With this explanation, we want to go beyond the idea
that the hypertension causes ‘organ damage’ or vice versa.
We want to show that a temporal relationship exists, but
one cannot confirm if hypertension or ‘organ damage’ is
the cause or the effect. We say that it is not important
whether the disease (organ damage) or the hypertension
comes first; the hypertension must be treated because it
causes worse outcomes.
In terms of hypertensive emergencies, some items
have not been determined: how much the arterial pres-
sure must increase, compared with the initial pressure
that is considered normal for the patient if he is normally
hypertensive or normotensive (<140/90 mmHg); how sud-
den the increase in arterial pressure must be or how steep
the increase should be; and, finally, the required duration
of the hypertension.article is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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emergencies’, it means to take account of the following
issues:
 The baroreflex, if appropriate, would not allow the
surge of the hypertensive crisis. It (the hypertensive
crisis) would be corrected and controlled to lower
values regardless of the cause of the hypertension.
The baroreflex might be temporarily disrupted, blinded
or reset to zero for the period of the crisis, as occurs
during physical activity, when hypertension and
tachycardia are permitted [1].
 The acute reaction to stress is important. When an
acute disease arises, hormones that can increase the
arterial pressure are released (ACTH–Cortisol and
adrenalin), and the release persists for at least 72 h [2].
 The acute release of noradrenaline from the
sympathetic endings associated with the vascular
endothelium results from tissue failure of the target
organs of the disease. This release occurs in some
specific diseases (severe pre-eclampsia, hypertensive
retinopathy and renal crisis).
 There could be an exaggerated increase in the
afterload (neurogenic pulmonary oedema,
pheochromocytoma).
 Prior diseases might be present (myocardiopathy,
coronaropathy, valvulopathy, atherosclerosis)
depending on the age of the patients (young,
elderly). The associated diseases preceding the
hypertensive crisis, especially those of the basic
organs that are essential for life and can trigger
positive feedback, make the clinical picture. The
occult, obvious or absent diseases define the signs
and the symptoms related to a hypertensive crisis.Review
Method
Literature search
The structure of the search strategy included a literature
search of PubMed, MEDLINE, Cochrane Library and
Google Scholar databases, as well as a review of the cited
references by the identified studies and a hand search of
relevant textbooks and reference works. The evaluated
studies which have been identified are (1) terms to search
for the health condition of interest: the diseases have been
defined using explicit criteria for establishing their
presence or not and (2) terms to search for the broad
population and setting of interest evaluated: presence
of a particular disease upon an hospital adult population
(more than 18 years old).
English randomised control trials were searched for,
which were published between January 1993 and February
2014.Study selection
The following inclusion criteria were applied: prospective
double-blind randomised controlled trials, experimental
animal work studies, case–control studies and recruiting
patients representative of the general sick population (i.e.,
adults over 18 years, diagnosed with the specific disease of
interest). We did a general review of the literature without
established hypothesis. The narrative review included ana-
lyses of 373 articles
Neurogenic pulmonary oedema (NPE)
Neurogenic pulmonary oedema (NPE) is one clinical vari-
ation of hypertensive emergency. A high level of hyperten-
sion and extreme release of noradrenaline characterises it.
Few reports on NPE have been written and it has not been
well studied: an acute, protein-rich lung oedema occurring
shortly after cerebral lesions associated with an acute rise
in the intracranial pressure (traumatic head injury, haem-
orrhage or ischemia). Younger patients without any car-
diopulmonary disease suffer from NPE. The age and sex
of the patient are unimportant, and acute cerebral injury,
endocranial hypertension and hyper-catecholaminaemia
are the required events [3, 4]. If these steps do not occur,
NPE does not develop.
The high level of norepinephrine causes hypertension,
increased pressure in the left atrium and the pulmonary
vasculature, electrocardiographic changes of ventricular
repolarisation and the release of myocardial enzymes such
as creatinine phosphokinase and troponin. The histologic
examination of the myocardium shows patchy necrosis of
the myocytes [5]. The seriousness of cerebral hypertension
directly relates to the level of the catecholamines, and
values over 2000 pg/ml are indicative of worse outcomes
[3]. If an efficacy input on sympathetic endings or the fail-
ure of the baroreflex to trigger a negative feedback is ob-
served, the cause has not been determined [6]. The type
and severity of the endocranial hypertension or the par-
ticipation of particular cerebral regions (points) likely play
leading roles at the beginning of the disease. During NPE,
the endocranial hypertension engages the hypothalamus
and is associated with acute extrapyramidal dysfunction of
the cerebellum and brainstem, which are the locations
of the baroreflex and the chemoreflex, respectively. This
might explain the defect of negative feedback and pressure
regulation of hypertensive crises [7].
Cases of pheochromocytoma associated with pulmon-
ary oedema show similar features [8–11].
Cardiac acute pulmonary oedema with arterial
hypertension
Cardiac acute pulmonary oedema is another clinical pres-
entation of a hypertensive crisis. This condition occurs in
older subjects with pre-existing, sometimes mild, cardiac
disease.
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epinephrine, are higher during cardiogenic pulmonary
oedema (CPE) compared with the values found in the
same patients when they are not in an acute crisis [12].
The relationship between CPE and hypertension is a
clinical and pathophysiologic link that explains the increase
in the afterload and the storage of plasma upstream of the
left cardiac chambers. The systolic function, normally
preserved during CPE, is non-influential in the patho-
physiology of CPE. The decrease in stroke volume, which
better represents the diastolic function, is used to differen-
tiate between symptoms or normality [13].
All of the types of acute hypertension, identified by the
level and the duration, increase the afterload, placing in-
creased pressure on the blood. The inability of acute
dilation of the cardiac chambers causes the storage of
blood in the left atrium and the pulmonary vascular
network. If mitral failure is coincident, different effects
develop.
Hypertensive emergency during pregnancy
The appropriate terminology needs to be defined to dis-
cuss on hypertensive crisis in pregnancy.
Pre-eclampsia is classified as severe when a pregnancy
that is more than 20 weeks of gestation is associated
with arterial pressure greater than 160 and/or 90 mmHg
and proteinuria greater than 1 g/24 h and there is organ
injury (oliguria, cerebral injury, pulmonary oedema). The
picture of HELLP syndrome (haemolysis, elevated liver en-
zymes and low-platelet count) that is sometimes associated
with pre-eclampsia is rarely characterised by severe hyper-
tension, which is not specific in its pathophysiology.
The cause of pre-eclampsia could be related to changes
in the vascular tissue system of the uterus and placenta
during pregnancy. The most likely hypothesis is that the
placenta causes sensitising to catecholamine or allows
soluble chemical substances to damage the vascular endo-
thelium, such as the soluble Fms-like tyrosine kinase 1
(sFlt 1) and soluble endoglin. Increased sFlt 1 has been
hypothesised to effectively reduce the concentration/
activity of vascular endothelial growth factor, resulting
in endothelial cell dysfunction, hypertension and pro-
teinuria [14–16]. These data have been confirmed by
experimental animal studies [17].
Reduced blood perfusion in all the organs develops be-
cause of severe vasoconstriction, which is a consequence
of the increased sensitivity of the vascular network to
pressurising chemical substances released from the uter-
oplacental system.
The mother’s organs suffer an acute blood supply
reduction.
Regarding the renal blood flow, swelling of the glom-
erular endothelium has been shown documented, and the
subendothelial deposits and detachment from the basementmembrane lead to vascular obstruction [18]. These lesions
are reversible in a time between 3 and 6 months post-
partum and couple with the disappearance of hypertension.
The vascular endothelium might be recognised as the target
organ of pre-eclampsia [19] because of sensitised, hormonal
hypertensive systems. The topic is not defined in the
literature, and there are conflicting reports about the
contributions of catecholamines vs. angiotensin and the
characteristics of the subjects [20].
Pregnancy and pre-eclampsia are unique conditions that
cannot be compared with non-pregnant subjects because
the two conditions seem to bestow a heightened sensitivity
to mediators. However, it seems that renin–angiotensin
[14] and catecholamines might contribute to the condi-
tions in humans [21, 22] and in animals [23].
Compared with hypertensive emergencies, the two
systems, renin–angiotensin and catecholamines, though
stimulated, are not as intensely increased as in neurogenic
pulmonary oedema or hypertensive pulmonary oedema.
For this reason, the target of their action appears to be
sensitised. The role of other mediators, such as the
endothelin system and vascular growth mediators, have
not yet been defined [24, 25].
Connective tissue diseases and scleroderma
Connective tissue diseases are a heterogeneous group of
disorders that are associated with the production of auto-
antibodies. Subclinical or overt renal manifestations are
frequently observed and complicate the clinical course of
these illnesses.
Scleroderma is distinctive. Approximately 2–5 % of pa-
tients with scleroderma suffer from ‘renal crisis’, which is
characterised by severe hypertension, rapidly progressive
glomerulonephritis and crescent glomerulonephritis [26]
with a decline in the renal function and thrombotic mi-
croangiopathy; this condition shows a significant benefit
from early angiotensin-converting-enzyme inhibitor ther-
apy and strict blood pressure control [27]. Renal crisis
constitutes a rare and dangerous complication, and the af-
fected patients present with prominent left heart failure
and hypertensive encephalopathy [28]. Renal failure could
be associated with moderate proteinuria without haema-
turia. Thrombotic microangiopathy is detected in 43 % of
the cases.
The pathological anatomical framework shows a throm-
botic microangiopathic process that particularly affects
small vessels. Vascular changes are accompanied by throm-
boses, the accumulation of myxoid material and the devel-
opment of onion-skin lesions and fibrointimal sclerosis
later in the disease course [29]. Vascular damage is a
primary event in the pathogenesis of scleroderma. The
progressive vascular injury includes persistent endothe-
lial cell activation/damage and apoptosis, intimal thick-
ening, delamination, vessel narrowing and obliteration.
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tone dysfunction and reduced capillary blood flow, with
consequent tissue ischemia and severe clinical manifes-
tations, such as digital ulcerations or amputations, pul-
monary arterial hypertension and scleroderma renal crisis.
The pathogenesis is thought to be a primary disease of the
endothelium followed by a ‘vasculitis’ or ‘endotheliitis’.
The release of specific mediators has a role in the onset
of the ‘renal crisis’, and it is likely that endothelin and
the renin–angiotensin system and aldosterone are in-
volved [30].
Hypertensive retinopathy and encephalopathy
In the literature, the two expressions ‘malignant hyperten-
sion’ and ‘accelerated hypertension’ should be considered
conceptually equivalent [31]. Hypertensive retinopathy is
characterised by a spectrum of retinal lesions associated
with chronic and stable arterial hypertension (isolated
microaneurysms, haemorrhages and cotton-wool spots,
grade II–IV Keith–Wagener score). The clinical picture
occurs in patients with certain characteristics: age greater
than 40 years, chronic hypertension and cardiovascular
risk factors, such as diabetes mellitus and dyslipidaemia.
The condition is associated with multi-organ damage
(renal failure, myocardial hypertrophy, atherosclerosis)
and is predictive of stroke, congestive heart failure and
cardiovascular mortality. The condition should be de-
fined as chronic hypertensive retinopathy.
There is another clinical condition, hypertensive retin-
opathy associated with acute hypertension, which defines
how malignant or accelerated the hypertension is in ref-
erence to organ damage and the speed of the disease
appearance. This condition is rare and occurs in only
1 % of hypertensive patients [31]; it affects patients of
younger ages. The affected individuals have with both
primary and secondary hypertension, and it is more
common in the black population of African origin.
The ophthalmoscopic examination shows the presence
of bilateral retinal haemorrhages and exudates, with or
without papilledema (grade IV Keith–Wagener score), and
the fluoroangiographic examination shows retinal oedema
[32]. This clinical picture is independent of cardiovascular
risk and is seen in young males with the severe and abrupt
appearance of arterial hypertension in patients with pheo-
chromocytoma [32–34].
Because of the easy accessibility of funduscopic exams,
the retinal changes play a paramount role in establishing
the diagnosis, but these changes appear to be associated
with obliterating endarteritis of other organs [35–37],
particularly of the kidney, which is a common place of
disease [38], as demonstrated by the reduction of filtra-
tion or by the presence of proteinuria.
Renal pathology is frequent, and renal endotheliitis is
linked to accelerated hypertension. The acute or malignantor accelerated hypertension should be considered as a
systemic disease with multiorgan involvement.
The causes of accelerated hypertension in a subject
that had normal blood pressure or mild hypertension
previously are not known. Studying the affected organs
has not helped to determine the cause of the accelerated
hypertension. The same histological lesions could be con-
sidered both as a cause and as an effect of acute hyper-
tension. In the first case, an insult causing endothelial
inflammation could lead to endotheliitis, which could
lead to the release of pro-hypertensive factors with posi-
tive feedback on hypertension.
In the second case, the acute hypertension, of unknown
cause, could be responsible for the endothelial injury.
Elevated blood pressure alone does not fully account
for the extent of the retinopathy. If the acute rise in
blood pressure appears to be the most likely cause of the
endothelial lesion, the signs of endothelial injury are fibrin-
oid necrosis, oedema and endovascular cell proliferation.
The vascular endothelium serves as an important auto-
crine and paracrine organ and maintains vascular homeo-
stasis by modulating the blood vessel tone and controlling
homeostatic and inflammatory responses [39]. Endothelial
dysfunction, which is suggested by the increase in inflam-
matory mediators, has been considered the onset of de-
generative and proliferative and/or subsequent exudative
lesions. From these observations, the concept of endothe-
liitis, a subacute inflammatory disease that could change
the blood flow and cause hypertension, was developed.
This endotheliitis is vascular onion-skin associated with
fibrinoid necrosis and arteriolar thrombosis involving
other organs such as the kidney (renal failure and/or
proteinuria) [31, 40], brain (posterior reversible enceph-
alopathy) [41], gut or pancreas [35–38].
Acute coronary ischemia
The natural history of acute ischemic coronary disease
(angina and myocardial infarction) and dissecting aneu-
rysms involves the appearance of pain.
Hypertension is a ‘life partner’ of ischemic cardiac dis-
eases; it comes first and influences the prognosis and
complications [42].
In the Western world, there is often a relationship be-
tween acute coronary syndrome and hypertension in
49–68 % of cases [43–45] and only 15 % of cases of age
less than 30 years [46]. The link between intramural he-
matomas and a dissecting aneurysm with hypertension
occurs in 100 % of cases [47].
Acute arterial hypertension, of new onset or associated
with a pre-existing chronic hypertension, is present during
episodes of myocardial ischemia, either transient ischemia
(angina) or extended ischemia with the appearance of ne-
crosis (myocardial infarction). The increased afterload and
the wall stress worsen the basic disease.
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disease, and there is pain. Hypertension triggers a positive
feedback mechanism that results in myocardial ischemia.
For this reason, a sharp reduction in blood pressure re-
duces the preload and the afterload and causes resolution
or improvement in the pain of cardiac angina.
The type C myelinated sympathetic fibres carry the sen-
sation of the pain. The stimulus to the nerve endings is
produced by the release tissue and endothelial and platelet
substances as a result of acute ischemia [48–50].
The pain represents an acute stressor that is adequate
to cause an increase in blood pressure [49] through the
release of substances such as adrenocorticotropic hormone
and prolactin from the anterior pituitary gland, glucocorti-
coids from the adrenal cortex, epinephrine from the adrenal
medulla and norepinephrine from the sympathetic nerves.
Any pain activates the sympathetic nervous system with
a release of norepinephrine, as has been demonstrated in
the clinic and experimentally [50–52]. There is no suffi-
cient evidence showing that the onset of hypertension
triggers the crisis of cardiac pain.
The de novo appearance of hypertension in cases of
cardiac angina or ongoing aortic dissections is the result
of ischemia, and the pain that occurs and the sympa-
thetic nervous system and the activation of the pituitary-
adrenal axis are intermediate mechanisms of disease.
Stroke (intracerebral haemorrhage, subarachnoid
haemorrhage, ischemic stroke)
The association of stroke with hypertension at the time
of its presentation varies according to age in 55 to 100 %
of the cases [53]. The appearance or worsening of pre-
existing hypertension is part of the natural history of
stroke. Within 72 h, the blood pressure values are re-
duced and return to the precrisis (precritical) levels.
The relationship between stroke and hypertension is
significant, and the degree of control in acute stroke has
been discussed [54].
The pathophysiological relationship between brain in-
jury and the development of hypertension remains un-
clear. The acute stress response has a significant role.
The extension of hypertension for up to 72 h after the
acute stress proves this role [4]. Reactions to stressors
typically involve either short- or long-term compensatory
changes in the cardiovascular, endocrine, immune and
somatosensory systems, which tend to maintain adequate
physiological function against the imbalance created by
the stressors [55]. Currently, there are not any elements to
justify the existence of other pathogenic factors as causes
of high blood pressure in stroke.
Conclusion
‘Hypertensive emergencies’ are a group of diseases
that are related to acute hypertension caused bycatecholamines, the sympathetic nervous system, the
vascular endothelium and acute stress. The hyperten-
sion is linked with the disease of one or more organs
(myocardium, kidney, brain) in which the hypertension
has a key role in the appearance of the pathology.
In clinical medicine, three novel concepts should be
established: (a) ‘acute’ hypertension exists and is charac-
terised by high arterial pressure values that could be tar-
geted in a short time (in a few hours or a few days), (b)
the acute hypertension is associated with organ disease
and (c) this acute hypertension should quickly be treated
because it causes more severe organ disease.
In ‘hypertensive urgency’, the stress has a low intensity,
and the organs can endure this stress without being
damaged.
Studies should explore why the regulation systems are
temporarily absent and are not able to adjust for the
hypertension.Proposal for new terminology
Having redefined the hypertensive emergency group of
diseases that have acute arterial hypertension as a factor
that could worsen the prognosis, we propose a classifica-
tion scheme based on the hypertension pathogenesis:
 Acute primary hypertension or reason (cause) of the
disease: a mechanism is established as the first
moment of hypertensive disease targeting the heart,
retina, brain and kidney. This category includes acute
cardiac pulmonary oedema, neurogenic pulmonary
oedema, pheochromocytoma, retinopathy and
hypertensive encephalopathy acute glomerulonephritis
and scleroderma.
 Acute secondary hypertension or caused by disease:
a disease causes changes in the circulating volume
or peripheral arteriolar resistance. This category
includes acute glomerulonephritis, scleroderma and
pre-eclampsia.
 Acute associated hypertension without causal
relationship: the disease is the effect of an acute
stress response. This category includes cardiac
angina, acute myocardial infarction, dissecting
aneurysm and stroke.
There could be different pathological mechanisms of the
same disease, and different factors contribute to these dif-
ferent mechanisms. For this reason, the diseases of acute
glomerulonephritis and scleroderma have been classified in
both the primary and acute hypertension as secondary
acute hypertension.Competing interest
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